A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ganaxolone IV in healthy volunteers

Trial Profile

A phase I study to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ganaxolone IV in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Ganaxolone (Primary)
  • Indications Status epilepticus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 11 Apr 2017 Results presented at the 6th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures 2017, according to a Marinus Pharmaceuticals media release.
    • 03 Nov 2016 Status changed from recruiting to completed, as per Marinus Pharmaceuticals media release.
    • 19 Oct 2016 Results were presented at the 141st Annual Meeting of the American Neurological Association (ANA), Marinus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top